Stock Quote
Progenics Pharmaceuticals, Inc. (PGNX.W) (NASD ADF)
$3.60
10 Nov 2009
-6.01%
$3.83
$3.69
500
$3.69
$3.60
$11.37
$3.71
1.42
164,914
PGNX.W
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Briner, Kurt | Chairman of the Board | -- |
| Maddon, Paul | Chief Executive Officer, Chief Science Officer, Director | 3,119,250 |
| Baker, Mark | President, Director | 1,512,760 |
Profile
Progenics Pharmaceuticals, Inc. (Progenics), is a biopharmaceutical company focusing on the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The Company's principal programs are directed... Full Description
Company Address
Progenics Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown NY 10591
P: +1914.7892800
F: +1914.7892817
777 Old Saw Mill River Road
Tarrytown NY 10591
P: +1914.7892800
F: +1914.7892817
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Nektar Therapeutics | $8.70 | +0.06 |
| Sucampo Pharmaceuticals, Inc. | $3.73 | +0.02 |
| Takeda Pharmaceutical Company Limited | ¥3,540.00 | -10.00 |
| PGNX.W | Industry | |
|---|---|---|
| P/E(TTM) | -- | 12.80 |
| P/S(TTM) | 2.52 | 29.90 |
| ROI(TTM) | -33.99 | 2.35 |
| ROE(TTM) | -34.72 | 3.59 |
| Consensus Recommendation | Hold |
|---|---|
| EPS Est. (Current Period) | -- |
| EPS Est. (Current Year) | -1.15 |
| Total Revenue | $5.47M |
| Net Income | $-15.17M |
| EPS | $-0.49 |
